Applied Therapeutics Announces Positive Sorbitol Reduction Data from on Ongoing Phase 3 Trial

(24/7 MARKET NEWS) – Applied Therapeutics, Inc. (Nasdaq:APLT) reported, this morning, positive sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial, a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily oral AT-007 in approximately 50 patients age 16-55 with SORD Deficiency in the US and Europe.

Applied Therapeutics is at $1.08, up $0.08 (+8.00%), on trading volume of 1.6 million premarket shares.

Its 52-week trading range is $0.4995 to $2.73. Its next key inflection point is $1.24.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.